CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 Genitourinary Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer
Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer
Dr. Powles on Durvalumab in Urothelial Cancer
Oncology Conference Articles
Vogelzang Emphasizes Aggressive Biopsies, Novel Therapies in Urothelial Carcinoma
At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.
Cabozantinib Regimens Active Across Multiple Advanced GU Malignancies
The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.
Combination Makes First-Line Case for Metastatic PD-L1+ RCC
Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.
Ipilimumab Broadens Nivolumab Activity in Urothelial Cancer
Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.
Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma
Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.
Durvalumab Impresses in Advanced Urothelial Cancer
The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.
Genomic Test Predicts Metastasis, Mortality in Prostate Cancer
The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.
Olaparib, Durvalumab Combo Active in Prostate Cancer
According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).
AR-FL mRNA Correlates With Response to AR-Targeted Therapies
According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.
Circulating Tumor DNA Can Advance Personalized Care in mCRPC
Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.
Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors
Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.
Durable Responders Emerge Even After Stopping Their PD-1/PD-L1 Therapy for Kidney Cancer
Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.
Burden of Cardiovascular Disease in Prostate Cancer
The Role of Patient Education in Side Effect Management
Sorting Through the Alphabet Soup of Evolving Treatments in CLL
Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.